 |
Ventrus Biosciences Announces Poster Presentation on the Quality of Compounded Topical Diltiazem Hydrochloride Formulations for Anal Fissure at the American Pharmacists Association Meeting
Mar 1, 2013
|
12.4 KB |
|
| |
NEW YORK, March 1, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced the poster presentation of the results from its study investigating the quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissures at the American Pharmacists Association Meeting currently underway in Los Angeles.
...
|
|
Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference
Feb 11, 2013
|
10.3 KB |
|
| |
NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the Leerink Swann Global Healthcare Conference on Thursday, February ...
|
|
Ventrus Biosciences Announces Full Exercise of Overallotment Option by Underwriters
Feb 7, 2013
|
11.7 KB |
|
| |
NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced that the underwriter of its previously announced public offering of common stock has exercised in full its overallotment option to purchase an additional 870,000 shares of common stock at the public offering price of $2.50 per share, less underwriting...
|
|
Ventrus Biosciences Announces $20 Million Financing
Jan 30, 2013
|
12.2 KB |
|
| |
NEW YORK, Jan. 30, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today the pricing of concurrent, separate underwritten offerings of (i) 5,800,000 shares of its common stock at a price to the public of $2.50 for each share of common stock, for expected gross proceeds of approximately $14,500,000, and (ii) 220,000 shares...
|
|
Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock
Jan 29, 2013
|
11.8 KB |
|
| |
NEW YORK, Jan. 29, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today that it is concurrently offering to sell, subject to market and other conditions, (i) shares of its common stock in an underwritten public offering, and (ii) shares of its Series A Convertible Preferred Stock ("Series A") in a separate underwritten p...
|
|
Ventrus Biosciences Reports Third Quarter 2012 Financial Results
Nov 13, 2012
|
11.7 KB |
|
| |
NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported financial results for the third quarter ended September 30, 2012.
"Following a successful discussion with the FDA and receipt of written feedback from our meeting, we now have a clear path forward toward the submission of a new drug applicatio...
|
|
Ventrus Biosciences to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Nov 8, 2012
|
9.5 KB |
|
| |
NEW YORK, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday...
|
|
Ventrus Biosciences Receives FDA Written Feedback, Targets NDA Filing for Diltiazem (VEN 307) in Anal Fissures Following Second Phase 3 Study
Nov 5, 2012
|
14.9 KB |
|
| |
NDA Filing Expected to Occur in Fourth Quarter 2013
Company to Host Conference Call and Presentation Today, November 5, at 10:00 a.m. ET
NEW YORK, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that...
|
|
Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations and Business Development
Sep 24, 2012
|
12.7 KB |
|
| |
NEW YORK, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it has appointed JP Benya Vice President, Commercial Operations and Business Development, effective September 24, 2012.
With over twenty year...
|
|
Ventrus Biosciences to Present at Upcoming Investor Conferences in September
Aug 29, 2012
|
9.0 KB |
|
| |
NEW YORK, Aug. 29, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the following upcoming investor conferences during the month of Septem...
|
|
Ventrus Biosciences Reports Second Quarter 2012 Financial Results
Aug 9, 2012
|
12.0 KB |
|
| |
NEW YORK, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported financial results for the second quarter ended June 30, 2012.
"Following the announcement of the positive results in the second quarter highlighting the potential of VEN 307 as a treatment of choice for anal fissures, Ventrus is now squarely fo...
|
|
Ventrus Biosciences Announces Results From Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease
Jun 25, 2012
|
14.4 KB |
|
| |
NEW YORK, June 25, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported that its Phase 3, randomized, double-blind, placebo-controlled clinical trial of iferanserin (VEN 309) in patients with hemorrhoidal disease did not meet its endpoints.
The Phase 3 trial randomized 603 patients to one of three, twice-daily tre...
|
|
Ventrus to Present at the Jefferies 2012 Global Healthcare Conference
May 30, 2012
|
8.6 KB |
|
| |
NEW YORK, May 30, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6th...
|
|
Ventrus to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 15, 2012
|
9.2 KB |
|
| |
NEW YORK, May 15, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the Bank of America Merrill Lynch 2012 Health Care Conference on Wedne...
|
|
Ventrus Biosciences Announces Positive Results From Pivotal Phase 3 Trial of Diltiazem (VEN 307) in Patients With Anal Fissures
May 14, 2012
|
69.8 KB |
|
| |
Treatment Arms Show Significant Improvement Over Placebo in Three Major Outcomes
Adverse Events Similar Between Treatment Arms and Placebo
Company to Host Conference Call and Presentation Today, May 14, at 10:00 a.m. ET
NEW YORK, May 14, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported positiv...
|
|
Ventrus Biosciences Reports First Quarter 2012 Financial Results
May 9, 2012
|
14.1 KB |
|
| |
NEW YORK, May 9, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported financial results for the first quarter ended March 31, 2012.
"Ventrus has achieved several important milestones in recent months, namely the completion of enrollment in pivotal Phase 3 clinical trials for our two lead product candidates, diltia...
|
|
Ventrus to Present at the 37th Annual Deutsche Bank Health Care Conference
May 1, 2012
|
8.6 KB |
|
| |
NEW YORK, May 1, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the 37th Annual Deutsche Bank Health Care Conference on Monday, May 7 a...
|
|
Ventrus Biosciences Completes Enrollment of Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease
Apr 30, 2012
|
11.4 KB |
|
| |
NEW YORK, April 30, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced that it has completed patient enrollment and randomization in the first Phase 3 clinical trial of iferanserin (VEN 309) in patients with grade 1-3 hemorrhoids. Data from the Phase 3 study are anticipated to be available in late June or early July 2012.
...
|
|
Ventrus Announces Two Studies Addressing Hemorrhoid Disease to be Presented at Digestive Disease Week Conference
Mar 8, 2012
|
10.1 KB |
|
| |
NEW YORK, March 8, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today that two abstracts submitted to the Digestive Disease Week conference (DDW), to be held in San Diego May 19-22, were accepted for presentation. Both abstracts present data from the omnibus patient survey commissioned by Ventrus of 10,202 consumers an...
|
|
Ventrus to Present at the 24th Annual ROTH OC Growth Stock Conference
Mar 5, 2012
|
8.6 KB |
|
| |
NEW YORK, March 5, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, Chairman and Chief Executive Officer, will be presenting at the 24th Annual ROTH OC Growth Stock Conference on Monday, March 12 a...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
